NCT01290211View on ClinicalTrials.gov

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Healthy
Interventions
DRUG

Maraviroc

maraviroc 300 mg BID x 5 days

DRUG

Fosamprenavir/ritonavir

fosamprenavir/ritonavir 700/100 mg BID x 10 days

DRUG

Maraviroc + Fosamprenavir/ritonavir

maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days

DRUG

Maraviroc

maraviroc 300 mg QD x 5 days

DRUG

Fosamprenavir/ritonavir

fosamprenavir/ritonavir 1400/100 mg QD x 10 days

DRUG

Maraviroc + Fosamprenavir/ritonavir

maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

ViiV Healthcare

INDUSTRY